{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:57:28Z","timestamp":1793923048474,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sandoz International GmbH"},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Febrile neutropenia (FN) is a\u00a0relatively common complication of cytotoxic chemotherapy. Prophylaxis with granulocyte colony-stimulating factor (G-CSF) can prevent FN and chemotherapy dose delays and enable the use of the higher dose intensities associated with a\u00a0survival benefit; however, G\u2011CSF is not always used optimally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Five medical oncologists with a\u00a0special interest in supportive care met to discuss the evidence for prophylaxis with G\u2011CSF to improve survival in cancer patients, identify reasons why this is not always done, and suggest potential solutions. The dose intensity of chemotherapy is critical for maximizing survival in cancer patients but may be reduced as a\u00a0result of hematological toxicity, such as FN. Use of G\u2011CSF has been shown to increase the chances of achieving the planned dose intensity in various cancers, including early-stage breast cancer and non-Hodgkin lymphoma. All physicians treating cancer patients should consider the use of G\u2011CSF prophylaxis in patients receiving chemotherapy, paying particular attention to patient-related risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>Strategies to optimize G\u2011CSF use include educating medical oncologists and pharmacists on the appropriate use of G\u2011CSF and informing patients about the efficacy of G\u2011CSF and its potential adverse effects. It is hoped that the evidence and opinions presented will help to encourage appropriate use of G\u2011CSF to support cancer patients at risk of FN in achieving the best possible outcomes from chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00508-023-02300-6","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:01:52Z","timestamp":1701054112000},"page":"362-368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment"],"prefix":"10.1007","volume":"136","author":[{"given":"Pere","family":"Gasc\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peeter","family":"Karihtala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lorenzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-9139","authenticated-orcid":false,"given":"Christoph","family":"Minichsdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"2300_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J; the ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27:v111\u20138.","journal-title":"Ann Oncol"},{"issue":"9","key":"2300_CR2","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/cam4.2955","volume":"9","author":"T Aagaard","year":"2020","unstructured":"Aagaard\u00a0T, Reekie\u00a0J, Jorgensen\u00a0M, Roen\u00a0A, Daugaard\u00a0G, Specht\u00a0L, et\u00a0al. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med. 2020;9(9):3033\u201342.","journal-title":"Cancer Med"},{"key":"2300_CR3","unstructured":"U.S. Department of Health and Human Resources. Common Terminology Criteria for Adverse Events (CTCAE). Version\u00a05.0. 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"issue":"10","key":"2300_CR4","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer\u00a0NM, Dale\u00a0DC, Crawford\u00a0J, Cosler\u00a0LE, Lyman\u00a0GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258\u201366.","journal-title":"Cancer"},{"key":"2300_CR5","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00520-016-3277-0","volume":"24","author":"Y Li","year":"2016","unstructured":"Li\u00a0Y, Klippel Z, Shih\u00a0X, Reiner\u00a0M, Wang\u00a0H, Page\u00a0JH. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer. 2016;24:4377\u201383.","journal-title":"Support Care Cancer"},{"issue":"6","key":"2300_CR6","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","volume":"13","author":"E Tai","year":"2017","unstructured":"Tai\u00a0E, Guy\u00a0GP, Dunbar\u00a0A, Richardson\u00a0LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J\u00a0Oncol Pract. 2017;13(6):e552\u2013e61.","journal-title":"J Oncol Pract"},{"issue":"4","key":"2300_CR7","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00520-020-05715-3","volume":"29","author":"A Averin","year":"2021","unstructured":"Averin\u00a0A, Silvia\u00a0A, Lamerato\u00a0L, Richert-Boe\u00a0K, Kaur\u00a0M, Sundaresan\u00a0D, et al. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Support Care Cancer. 2021;29(4):2179\u201386.","journal-title":"Support Care Cancer"},{"issue":"3","key":"2300_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford\u00a0J, Ozer\u00a0H, Stoller\u00a0R, Johnson\u00a0D, Lyman\u00a0G, Tabbara\u00a0I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N\u00a0Engl J Med. 1991;325(3):164\u201370.","journal-title":"N Engl J Med"},{"issue":"11","key":"2300_CR9","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1200\/JCO.1994.12.11.2471","volume":"12","author":"American Society of Clinical Oncology","year":"1994","unstructured":"American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J\u00a0Clin Oncol. 1994;12(11):2471\u2013508.","journal-title":"J Clin Oncol"},{"issue":"20","key":"2300_CR10","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","volume":"18","author":"H Ozer","year":"2000","unstructured":"Ozer\u00a0H, Armitage\u00a0JO, Bennett\u00a0CL, Crawford\u00a0J, Demetri\u00a0GD, Pizzo\u00a0PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J\u00a0Clin Oncol. 2000;18(20):3558\u201385.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2300_CR11","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel\u00a0CL, Wojtukiewicz\u00a0MZ, Carroll\u00a0RR, Tjulandin\u00a0SA, Barajas-Figueroa\u00a0LJ, Wiens\u00a0BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a\u00a0multicenter, double-blind, placebo-controlled phase\u00a0III study. J\u00a0Clin Oncol. 2005;23(6):1178\u201384.","journal-title":"J Clin Oncol"},{"key":"2300_CR12","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines for Hematopoietic Growth Factors. Version\u00a02. 2023. Available from: www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493"},{"issue":"1","key":"2300_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro\u00a0MS, Bohlius\u00a0J, Cameron\u00a0DA, Dal Lago\u00a0L, Donnelly\u00a0JP, Kearney\u00a0N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332.","journal-title":"Eur J Cancer"},{"issue":"28","key":"2300_CR14","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith\u00a0TJ, Bohlke\u00a0K, Lyman\u00a0GH, Carson\u00a0KR, Crawford\u00a0J, Cross\u00a0SJ, et\u00a0al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J\u00a0Clin Oncol. 2015;33(28):3199\u2013212.","journal-title":"J Clin Oncol"},{"key":"2300_CR15","unstructured":"European Society for Medical Oncology. Supportive care strategies during the COVID-19 pandemic. Available from: www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/supportive-care-in-the-covid-19-era"},{"key":"2300_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/ahe.09.31","volume":"5","author":"M Prabhakar","year":"2009","unstructured":"Prabhakar\u00a0M, Ershler\u00a0WB, Longo\u00a0DL. Bone marrow, thymus and blood: changes across the lifespan. Aging Health. 2009;5:385\u201393.","journal-title":"Aging Health"},{"issue":"4","key":"2300_CR17","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00520-018-4481-x","volume":"27","author":"H Link","year":"2019","unstructured":"Link\u00a0H, Kerkmann\u00a0M, Holtmann\u00a0L, Ortner\u00a0P. G\u2011CSF guideline adherence in Germany, an update with a\u00a0retrospective and representative sample survey. Support Care Cancer. 2019;27(4):1459\u201369.","journal-title":"Support Care Cancer"},{"issue":"14","key":"2300_CR18","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199504063321401","volume":"332","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna\u00a0G, Valagussa\u00a0P, Moliterni\u00a0A, Zambetti\u00a0M, Brambilla\u00a0C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20\u00a0years of follow-up. N\u00a0Engl J Med. 1995;332(14):901\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"2300_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","volume":"114","author":"I Chirivella","year":"2009","unstructured":"Chirivella\u00a0I, Bermejo\u00a0B, Insa\u00a0A, Perez-Fidalgo\u00a0A, Magro\u00a0A, Rosello\u00a0S, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114(3):479\u201384.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"2300_CR20","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/annonc\/mdv389","volume":"26","author":"RC Leonard","year":"2015","unstructured":"Leonard\u00a0RC, Mansi\u00a0JL, Keerie\u00a0C, Yellowlees\u00a0A, Crawford\u00a0S, Benstead\u00a0K, et al. A\u00a0randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (\u2019SPROG\u2019 trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann Oncol. 2015;26(12):2437\u201341.","journal-title":"Ann Oncol"},{"issue":"12","key":"2300_CR21","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S1470-2045(22)00632-5","volume":"23","author":"L Del Mastro","year":"2022","unstructured":"Del Mastro\u00a0L, Poggio\u00a0F, Blondeaux\u00a0E, De Placido\u00a0S, Giuliano\u00a0M, Forestieri\u00a0V, et al. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a\u00a0randomised, phase\u00a03\u00a0trial. Lancet Oncol. 2022;23(12):1571\u201382.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2300_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly\u00a0A, Bron\u00a0D, Van Hoof\u00a0A, De Bock\u00a0R, Berneman\u00a0Z, Ferrant\u00a0A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B\u2011cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87(4):277\u201383.","journal-title":"Ann Hematol"},{"issue":"5","key":"2300_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","volume":"87","author":"R Pettengell","year":"2008","unstructured":"Pettengell\u00a0R, Schwenkglenks\u00a0M, Bosly\u00a0A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87(5):429\u201330.","journal-title":"Ann Hematol"},{"issue":"3","key":"2300_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh\u00a0M, Trumper\u00a0L, Kloess\u00a0M, Schmits\u00a0R, Feller\u00a0AC, Rube\u00a0C, et al. Two-weekly or 3\u2011weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634\u201341.","journal-title":"Blood"},{"issue":"3","key":"2300_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh\u00a0M, Trumper\u00a0L, Kloess\u00a0M, Schmits\u00a0R, Feller\u00a0AC, Rudolph\u00a0C, et al. Two-weekly or 3\u2011weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626\u201333.","journal-title":"Blood"},{"issue":"4","key":"2300_CR26","first-page":"496","volume":"91","author":"E Brusamolino","year":"2006","unstructured":"Brusamolino\u00a0E, Rusconi\u00a0C, Montalbetti\u00a0L, Gargantini\u00a0L, Uziel\u00a0L, Pinotti\u00a0G, et al. Dose-dense R\u2011CHOP-14 supported by pegfilgrastim in patients with diffuse large B\u2011cell lymphoma: a\u00a0phase\u00a0II study of feasibility and toxicity. Haematologica. 2006;91(4):496\u2013502.","journal-title":"Haematologica"},{"key":"2300_CR27","first-page":"765","volume":"41(12","author":"DC Moore","year":"2016","unstructured":"Moore\u00a0DC. Drug-induced neutropenia: a\u00a0focus on rituximab-induced late-onset neutropenia. P\u00a0T. 2016;41(12:765\u20138.","journal-title":"P T"},{"issue":"10184","key":"2300_CR28","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran\u00a0SE, Homann\u00a0N, Pauligk\u00a0C, Goetze\u00a0TO, Meiler\u00a0J, Kasper\u00a0S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a\u00a0randomised, phase\u00a02\/3\u00a0trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"key":"2300_CR29","unstructured":"ClinicalTrials.gov. Phase\u00a0II study of atezolizumab + FLOT vs. FLOT alone in patients with gastric cancer and GEJ (DANTE). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03421288"},{"key":"2300_CR30","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2022.40.16_suppl.4003","volume":"40","author":"SE Al-Batran","year":"2022","unstructured":"Al-Batran\u00a0SE, Lorenzen S, Thuss-Patience\u00a0PC, Homann\u00a0N, Schenk\u00a0M, Lindig\u00a0U, et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a\u00a0randomized, multicenter, phase\u00a0IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J\u00a0Clin Oncol. 2022;40:4003.","journal-title":"J\u00a0Clin Oncol."},{"issue":"7","key":"2300_CR31","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1093\/oncolo\/oyac055","volume":"27","author":"C Canton","year":"2022","unstructured":"Canton\u00a0C, Boussari\u00a0O, Boulin\u00a0M, Le Malicot\u00a0K, Taieb\u00a0J, Dahan\u00a0L, et al. Impact of G\u2011CSF prophylaxis on chemotherapy dose-intensity, link between dose-intensity and survival in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2022;27(7):e571\u2013e9.","journal-title":"Oncologist"},{"issue":"9","key":"2300_CR32","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","volume":"29","author":"GH Lyman","year":"2018","unstructured":"Lyman\u00a0GH, Yau\u00a0L, Nakov\u00a0R, Krendyukov\u00a0A. Overall survival and risk of second malignancies with cancer chemotherapy and G\u2011CSF support. Ann Oncol. 2018;29(9):1903\u201310.","journal-title":"Ann Oncol"},{"issue":"4","key":"2300_CR33","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/annonc\/mdv619","volume":"27","author":"J Truong","year":"2016","unstructured":"Truong\u00a0J, Lee\u00a0EK, Trudeau\u00a0ME, Chan\u00a0KK. Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a\u00a0systematic review and meta-analysis. Ann Oncol. 2016;27(4):608\u201318.","journal-title":"Ann Oncol"},{"issue":"1","key":"2300_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13187-019-01638-8","volume":"35","author":"A Hawkins","year":"2020","unstructured":"Hawkins\u00a0A, Murphy\u00a0A, McNamara\u00a0M, Gawade\u00a0PL, Belani\u00a0R, Kelsh\u00a0MA. A\u00a0survey of oncologists\u2019 perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J\u00a0Cancer Educ. 2020;35(1):178\u201386.","journal-title":"J Cancer Educ"},{"issue":"6","key":"2300_CR35","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1177\/1078155218792698","volume":"25","author":"AR Zullo","year":"2019","unstructured":"Zullo\u00a0AR, Lou\u00a0U, Cabral\u00a0SE, Huynh\u00a0J, Berard-Collins\u00a0CM. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. J\u00a0Oncol Pharm Pract. 2019;25(6):1357\u201365.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"2300_CR36","first-page":"e97","volume":"2016","author":"CK Dittrich","year":"2016","unstructured":"Dittrich\u00a0CK, Kosty M, Jezdic\u00a0S, Pyle\u00a0D, Berardi\u00a0R, Bergh\u00a0J, et\u00a0al. ESMO \/ ASCO recommendations for a\u00a0global curriculum in medical oncology edition. Esmo Open. 2016;2016(1):e97.","journal-title":"Esmo Open"},{"issue":"3","key":"2300_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12788\/jcso.0117","volume":"13","author":"JN Bernens","year":"2015","unstructured":"Bernens\u00a0JN, Hartman\u00a0K, Curley\u00a0B, Wen\u00a0S, Rogers\u00a0J, Abraham\u00a0J, et\u00a0al. Assessing the impact of a\u00a0targeted electronic medical record intervention on the use of growth factor in cancer patients. J\u00a0Community Support Oncol. 2015;13(3):113\u20136.","journal-title":"J Community Support Oncol"},{"key":"2300_CR38","unstructured":"European Medicines Agency. Ziextenzo. Summary of Product Characteristics. Published 2019. Available From: wwwe.ema.europa.eu\/en\/documents\/product-information\/ziextenzo-epar-product-information_en.pdf."},{"key":"2300_CR39","unstructured":"European Medicines Agency. Zarzio. Summary of Product Characteristics. Updated 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zarzio-epar-product-information_en.pdf"},{"issue":"10","key":"2300_CR40","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1046\/j.1537-2995.1999.39101136.x","volume":"39","author":"J McCullough","year":"1999","unstructured":"McCullough\u00a0J, Clay\u00a0M, Herr\u00a0G, Smith\u00a0J, Stroncek\u00a0D. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion. 1999;39(10):1136\u201340.","journal-title":"Transfusion"},{"issue":"17","key":"2300_CR41","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","volume":"28","author":"GH Lyman","year":"2010","unstructured":"Lyman\u00a0GH, Dale\u00a0DC, Wolff\u00a0DA, Culakova\u00a0E, Poniewierski\u00a0MS, Kuderer\u00a0NM, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a\u00a0systematic review. J\u00a0Clin Oncol. 2010;28(17):2914\u201324.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2300_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40259-020-00411-4","volume":"34","author":"P Cornes","year":"2020","unstructured":"Cornes\u00a0P, Gascon\u00a0P, Vulto\u00a0AG, Aapro\u00a0M. Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs. 2020;34(3):255\u201363.","journal-title":"BioDrugs"},{"issue":"8","key":"2300_CR43","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1200\/OP.20.01047","volume":"17","author":"E Li","year":"2021","unstructured":"Li\u00a0E, Mezzio\u00a0DJ, Campbell\u00a0D, Campbell\u00a0K, Lyman\u00a0GH. Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a\u00a0cost-effectiveness analysis. Jco Oncol Pract. 2021;17(8):e1235\u2013e45.","journal-title":"Jco Oncol Pract"},{"issue":"1","key":"2300_CR44","first-page":"1127","volume":"18","author":"H Roche","year":"2018","unstructured":"Roche\u00a0H, Eymard\u00a0JC, Radji\u00a0A, Prevost\u00a0A, Diab\u00a0R, Lamuraglia\u00a0M, et\u00a0al. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a\u00a0prospective multicentre study in France in patients with solid tumours (the ZOHe study). BMC. Cancer. 2018;18(1):1127.","journal-title":"Cancer"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02300-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T05:15:50Z","timestamp":1717650950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02300-6"}},"subtitle":["An expert view"],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":44,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2300"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02300-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Gasc\u00f3n is Editor-in-Chief of <i>Clinical and Translational Oncology<\/i>. A.\u00a0Awada has acted in an advisory role for Amgen, AstraZeneca, Bayer, Daiichi, Eisai, Genomic Health, Hengrui, Innate, Ipsen, LEO Pharma, Lilly, Merck, MSD, Novartis, Pfizer, and Seattle Genetics, and has received speaker fees for Amgen, AstraZeneca, Bayer, Daiichi, Eisai, Genomic Health, Ipsen, LEO Pharma, Lilly, Merck, MSD, Novartis, Pfizer, and Seattle Genetics; his institute has received research grants from Bristol Myers Squibb and Roche. P.\u00a0Karihtala has received honoraria from Amgen and Sandoz. C.\u00a0Minichsdorfer has received honoraria from Sandoz, Boehringer Ingelheim, MSD, and Amgen, as well as travel grants from MSD and Merck Darmstadt. S.\u00a0Lorenzen declares that she has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}